Completing (or Continuing) Your Training? Let's Stay in Touch! During and just after your training, the right support is critical. Ensure we're providing you with support tailored to your needs. If ...

The Centers for Medicare and Medicaid Services' (CMS') new Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model will begin July 5, 2026. In preparation for the launch, the agency ...

CMS has proposed ending Coverage with Evidence Development (CED) requirements for patients with symptomatic severe aortic stenosis (AS) while expanding CED to include patients with asymptomatic severe ...

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...

The U.S. Food and Drug Administration (FDA) has taken an unprecedented step by authorizing the marketing of four Glas e-cigarettes, including the following pod flavors: Classic Menthol, Fresh Menthol, ...

When compared with angiography-guided PCI, IVUS-guided PCI was found to be not superior in patients with complex coronary arteries according to results from the IVUS-CHIP trial or in patients with ...

A culturally tailored food-is-medicine intervention significantly reduced systolic blood pressure (SBP) in Black and Hispanic adults with hypertension, compared with those who received an equivalent ...

Among patients with severe left ventricular (LV) dysfunction and severe coronary heart disease undergoing complex PCI, elective LV unloading with a microaxial flow pump did not reduce the risk of ...

Artificial intelligence (AI) is increasingly touching more aspects of modern life, offering great promise, but also great risk. The great potential and concerning influences of AI on medicine, ...

Lowering LDL-C to <55 mg/dL in patients with atherosclerotic cardiovascular disease (ASCVD) reduced the rate of major cardiovascular events by one-third, according to the Ez-PAVE trial presented ...

Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...